Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics Inc. has demonstrated strong revenue growth, reporting a year-over-year increase of 57% in new patient starts (NPS) alongside higher-than-expected performance in the pharmacy channel. The company's management has revised their revenue estimates for 2025 and 2026 upwards, projecting $97.5 million and $136 million, respectively, and has bolstered their 4Q25 revenue forecast to $29.8 million due to robust new prescription momentum and a solid durable medical equipment (DME) mix. With a significant portion of NPS coming from conversions of multiple daily injection patients and the successful expansion of sales territories, Beta Bionics appears well-positioned to maintain a premium growth profile with a projected compound annual growth rate (CAGR) of 30-40% from 2024 to 2028.

Bears say

Beta Bionics Inc. faces several critical challenges that contribute to a negative outlook on its stock, primarily surrounding its ability to capture market share with its iLet Bionic Pancreas amidst competitive pressures, which could adversely affect revenue and profitability. Additionally, the company may experience setbacks due to delays in clinical development timelines and the lack of an FDA marketing label, hindering the adoption of its products. Lastly, potential capital needs may lead to shareholder dilution, compounded by uncertain Medicare reimbursement policies that could impose further obstacles to the company's growth trajectory.

BBNX has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 9 analysts, BBNX has a Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.